A feasibility study to inform the design of a randomised controlled trial to identify the most clinically and cost effective length of anticoagulation with low molecular weight heparin In the treatment of Cancer Associated Thrombosis

Trial Profile

A feasibility study to inform the design of a randomised controlled trial to identify the most clinically and cost effective length of anticoagulation with low molecular weight heparin In the treatment of Cancer Associated Thrombosis

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Dalteparin sodium (Primary) ; Enoxaparin sodium (Primary) ; Tinzaparin sodium (Primary)
  • Indications Thrombosis; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms ALICAT
  • Most Recent Events

    • 14 Oct 2014 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
    • 08 Apr 2014 Accrual to date is 2% according to United Kingdom Clinical Research Network record.
    • 06 Mar 2014 Accrual to date is 1% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top